BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 32929383)

  • 1. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
    Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS
    Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
    Front Immunol; 2021; 12():677169. PubMed ID: 34354701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.
    Wang Q; Li M; Yang M; Yang Y; Song F; Zhang W; Li X; Chen K
    Aging (Albany NY); 2020 Feb; 12(4):3312-3339. PubMed ID: 32091408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients.
    Shi R; Bao X; Unger K; Sun J; Lu S; Manapov F; Wang X; Belka C; Li M
    Theranostics; 2021; 11(10):5061-5076. PubMed ID: 33754044
    [No Abstract]   [Full Text] [Related]  

  • 6. Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma.
    Yao B; Wang L; Wang H; Bao J; Li Q; Yu F; Zhu W; Zhang L; Li W; Gu Z; Fei K; Zhang P; Zhang F; Huang X
    Aging (Albany NY); 2021 Apr; 13(8):11381-11410. PubMed ID: 33839701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P2RX7B is a new theranostic marker for lung adenocarcinoma patients.
    Benzaquen J; Dit Hreich SJ; Heeke S; Juhel T; Lalvee S; Bauwens S; Saccani S; Lenormand P; Hofman V; Butori M; Leroy S; Berthet JP; Marquette CH; Hofman P; Vouret-Craviari V
    Theranostics; 2020; 10(24):10849-10860. PubMed ID: 33042257
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
    Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
    Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
    Sui P; Liu X; Zhong C; Sha Z
    Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
    Li R; Tong R; Zhang JL; Zhang Z; Deng M; Hou G
    J Cancer Res Clin Oncol; 2024 May; 150(5):246. PubMed ID: 38722401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock factor 5 correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma.
    Aizemaiti R; Wu Z; Tang J; Yan H; Lv X
    Int J Med Sci; 2021; 18(2):448-458. PubMed ID: 33390814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.
    Liao Y; He D; Wen F
    Immunogenetics; 2021 Oct; 73(5):369-380. PubMed ID: 34302518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment.
    Tan Q; Huang Y; Deng K; Lu M; Wang L; Rong Z; Zhao W; Li S; Xu Z; Fan L; Li K; Li Z
    J Cell Biochem; 2020 Nov; 121(11):4569-4579. PubMed ID: 32030808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of
    Zheng H; Cui Y; Li X; Du B; Li Y
    Clin Lung Cancer; 2019 Nov; 20(6):420-428. PubMed ID: 31300363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
    Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma.
    Kurbatov V; Balayev A; Saffarzadeh A; Heller DR; Boffa DJ; Blasberg JD; Lu J; Khan SA
    Ann Thorac Surg; 2020 Feb; 109(2):343-349. PubMed ID: 31568747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
    Zhang J; Sun G; Mei X
    Cancer Biomark; 2019; 26(3):367-373. PubMed ID: 31594212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.